Article · 18 Dec 2025
Conference abstractPublished 1 Sep 2020
Efficacy of cabozantinib as third or fourth line therapy in patients with advanced hepatocellular carcinoma
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Background: Cabozantinib is approved as second line therapy in patients with progression after sorafenib in hepatocellular carcinoma (HCC) patients, however the study about efficacy of cabozantinib as third or fourth line therapy (esp. in the case of progression after nivolumab). We aimed to evaluate the efficacy and safety of cabozantinib as 3rd & 4th line treatment in patients with advanced HCC with progressive disease after TKI and nivolumab. Methods: Eligible advanced HCC patients with documented radiological evidence of disease progression with previous 1st & 2nd line systemic treatment were recruited in our hospital from Mar 2019 to Aug 2019. All patients initially received cabozantinib 60mg daily as fixed starting dose every 4 weeks for unlimited cycles untile radiologic progression. Results: Six patients (3rd line Tx in one patient, 4th line Tx in five patients) were enrolled in the study. All five patients previously received three sequential therapies (sorafenib → regorafenib → nivolumab) and only one patient received two sequential therapies (sorafenib → nivolumab). The median level of AFP was 128.6 ng/mL (1.3-20948), that of PIVKA was 2131 mAU/Ml (1057-29440) in 2L group. The median OS was 5 months (range 3-6.5) and the median PFS was 4 months (range 3-6.5). The OS and in sorafenib responder & non responder were not different significantly (median OS 4 vs 3 months; p-value=0.503). All patient achieved stable disease. Grade 3 or 4 adverse events occurred in 3 patients (66.6%). The most common high-grade events fatigue (50%) and diarrhea (16%). Interruption of drug was happened in all patients within 8 weeks and dose reduction was occurred in 4 patients (66.6%). Conclusions: Our study suggests that cabozantinib can be relatively effective and safe strategy as 3rd and 4th line therapy in HCC patients refractory for previous systemic therapy. A further well controlled, large scaled study to prove survival benefit is recommended. Biography: Sang Youn Hwang is currently affiliated to the Department of Internal Medicine and Gastrointestinal Cancer Centre in Dongnam Institute of Radiological & Medical Sciences, Republic of Korea
Subjects
Oncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Tumour Research & Reports.
Article · 18 Dec 2025
Therapeutic Strategies in the Management of Intracranial Neoplasm
Article · 18 Dec 2025
Reprogramming the Tumor Microenvironment: Emerging Insights Shaping the Future of Cancer Research
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Tumour Research & Reports
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Sang Youn Hwang”
